Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion in rats

被引:15
作者
Kim, SJ
Choi, HK
Lee, YB
机构
[1] Chonnam Natl Univ, Coll Pharm, Buk Gu, Kwangju 500757, South Korea
[2] Chonnam Natl Univ, Res Inst Drug Dev, Buk Gu, Kwangju 500757, South Korea
[3] Chosun Univ, Coll Pharm, Dong Gu, Kwangju 501759, South Korea
关键词
cyclosporin A; O/W-emulsion; pharmacokinetics; pharmacodynamics;
D O I
10.1016/S0378-5173(02)00490-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and pharmacodynamics of the cyclosporin A (CSA) O/W-emulsion were studied after intravenous and oral administration to Sprague-Dawley rats. Two commercial products, CIPOL Inj.(R) and Sandimmun Neoral(R), were used as the reference formulations. CSA concentration and lymphocyte populations in whole blood were measured by TDxFLx(R) and Coulter STKS(R), respectively. The pharmacokinetic and pharmacodynamic parameters were obtained by fitting experimental data to two-compartment model and to indirect pharmacodynamic model, respectively, using WINNONLIN. The area under the concentration-time curve (AUC), terminal half-lives (T-1/2), total clearance (CLt) and relative bioavailability (F) after intravenous administration of CSA O/W-emulsion were not significantly different from those of intravenous administration of CIPOL Inj.(R) (P > 0.05). In oral administration, AUC and C-max of CSA O/W-emulsion were significantly decreased (P < 0.05), while T-1/2, MRT, T a and F were not significantly different (P > 0.05) from those of Sandimmun Neoral(R). However, the area between the baseline and effect curves (ABEC) and pharmacodynamic efficiency (EFF) of CSA O/W-emulsion were significantly greater than those of references regardless of routes of administration (P < 0.05). The pharmacodynamic availability (F-PD) of CSA O/W-emulsion was 1.79- and 2.13-fold higher than that of CIPOL Inj.(R) and Sandimmun Neroal(R) (P < 0.05), respectively. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:149 / 156
页数:8
相关论文
共 29 条
[1]   ASSESSMENT OF CYCLOSPORIN-A IN WHOLE-BLOOD AND PLASMA IN 5 PATIENTS WITH DIFFERENT HEMATOCRITS [J].
AGARWAL, RP ;
MCPHERSON, RA ;
THREATTE, GA .
THERAPEUTIC DRUG MONITORING, 1985, 7 (01) :61-65
[2]   PHARMACODYNAMIC MONITORING OF CYCLOSPORINE [J].
AWNI, WM .
CLINICAL PHARMACOKINETICS, 1992, 23 (06) :428-448
[3]  
BERG AP, 1998, TRANSPLANTATION, V65, P1066
[4]  
BONTEMPO JA, 1997, DEV BIOPHARMACEUTICA
[5]  
CAVANAK T, 1986, PROG ALLERGY, V38, P65
[6]   ABSORPTION AND DISPOSITION OF COLLOIDAL DRUG DELIVERY SYSTEMS .1. HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC (HPLC) ANALYSIS OF A CYCLOSPORINE EMULSION [J].
CORVARI, SJ ;
HOLLENBECK, RG ;
LESLIE, J ;
PLAISANCE, KI ;
YOUNG, D .
PHARMACEUTICAL RESEARCH, 1991, 8 (01) :40-42
[7]   COMPARISON OF 4 BASIC MODELS OF INDIRECT PHARMACODYNAMIC RESPONSES [J].
DAYNEKA, NL ;
GARG, V ;
JUSKO, WJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (04) :457-478
[8]   ENHANCEMENT OF THE ORAL ABSORPTION OF CYCLOSPORINE IN MAN [J].
DREWE, J ;
MEIER, R ;
VONDERSCHER, J ;
KISS, D ;
POSANSKI, U ;
KISSEL, T ;
GYR, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (01) :60-64
[9]   LIPOSOMAL FORMULATIONS OF CYCLOSPORINE-A - INFLUENCE OF LIPID TYPE AND DOSE ON PHARMACOKINETICS [J].
FAHR, A ;
HOLZ, M ;
FRICKER, G .
PHARMACEUTICAL RESEARCH, 1995, 12 (08) :1189-1198
[10]  
Ferron GM, 1998, J PHARMACOL EXP THER, V286, P191